EJNMMI reports最新文献

{"title":"FAPI: a solution to all, what about NENs?","authors":"Ozgul Ekmekcioglu, Filiz Celik, Simon Hughes, Meltem Ocak, Fred Verzijlbergen, Stefano Fanti, Christophe M Deroose","doi":"10.1186/s41824-026-00321-8","DOIUrl":"10.1186/s41824-026-00321-8","url":null,"abstract":"<p><p>Fibroblast activation protein (FAP)-targeted PET imaging is an emerging technique that images the tumor stroma by targeting cancer-associated fibroblasts, offering high tumor-to-background contrast and improved lesion detection in tumors with low [¹⁸F]FDG avidity. Given the central role of CAFs in tumor progression and therapy response, FAPI PET has gained interest in neuroendocrine neoplasms (NENs), where stromal imaging may provide complementary information to conventional modalities. This review evaluates the biological rationale, current evidence, and potential clinical role of FAPI PET in the imaging and management of NENs.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13346405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET/CT contouring techniques in neuroendocrine neoplasms: a state-of-the-art scoping review.","authors":"Jacky Wt Chen, Paul J Roach, Nick Pavlakis, Elizabeth J Bernard, Roderick Clifton-Bligh, Dale L Bailey, David L Chan","doi":"10.1186/s41824-026-00307-6","DOIUrl":"10.1186/s41824-026-00307-6","url":null,"abstract":"<p><strong>Background: </strong>Neuroendocrine neoplasms (NENs) are often metastatic at diagnosis and show great variation in primary site and biological behaviour. Although PET is often used to image NENs, contouring is challenging because NEN lesions are heterogenous. This scoping review examines the literature on NEN contouring in clinical settings.</p><p><strong>Methods: </strong>The scoping review follows the PRISMA-ScR guidelines. Published studies between 2010 and 2025 and conference abstracts and proceedings between 2023 and 2025 were included. Eligible studies included studies with at least 5 patients with NEN, involved PET imaging analysis with the measurement of at least one quantitative variable, and used a thresholding method to determine lesion contours.</p><p><strong>Results: </strong>Thirty-seven articles and 17 conference abstracts were included in the review. Sixteen articles investigated flat contouring methods, 11 investigated relative contouring approaches, 3 investigated both, 6 used manual contouring exclusively, and 1 did not explicitly describe the contouring method. Twenty-five articles used radiopharmaceuticals targeting somatostatin receptors (SSTR) only, 5 used [¹⁸F]FDG only, 6 used dual tracers, and 1 used [¹⁸F]F-DOPA. Included studies confirmed the prognostic importance of SSTR and [¹⁸F]FDG volumetric parameters and [¹⁸F]FDG SUV_max. There was little agreement regarding the prognostic value of other measurable quantitative parameters.</p><p><strong>Conclusions: </strong>Flat contouring methods were most commonly used for the contouring of NENs and are clinically applicable. Therefore, investigating the prognostic value of quantitative parameters derived from flat contouring methods could yield an optimised NEN lesion contouring methodology.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An intrathyroidal cystic parathyroid adenoma localised with [¹⁸F]fluorocholine PET/CT in pregnancy.","authors":"Sameer K Dave, Claire Mok, Stan Sidhu, John Turchini, Margaret Layton, Weng Sam, David Medveczky, Jeremy Hoang","doi":"10.1186/s41824-026-00311-w","DOIUrl":"10.1186/s41824-026-00311-w","url":null,"abstract":"<p><p>Primary hyperparathyroidism during pregnancy is rare but associated with substantial maternal and foetal morbidity, necessitating timely diagnosis and intervention. Intrathyroidal parathyroid adenomas account for as few as 0.7% of parathyroid adenomas, while cystic parathyroid adenomas represent an even smaller subset. The coexistence of both is exceedingly uncommon, with only nine cases reported and none previously described in pregnancy or using [¹⁸F]fluorocholine PET/CT for localisation. We describe a 37-year-old pregnant woman with PTH-dependent hypercalcaemia which persisted following initial parathyroidectomy. A left thyroid lesion with mixed cystic and peripheral enhancing components was detected on ultrasound and multiphase IV contrast CT (4D CT) but remained indeterminate. To minimise foetal radiation exposure, an ultra-low dose protocol [¹⁸F]fluorocholine PET/CT was performed at 16 weeks' gestation, demonstrating peripheral tracer uptake consistent with a hyperfunctioning intrathyroidal cystic parathyroid adenoma. Ultrasound-guided sampling confirmed markedly elevated cyst fluid PTH. Definitive management with left hemithyroidectomy at 23 weeks' gestation resulted in normalisation of biochemistry and an uncomplicated term delivery. This first reported case of intrathyroidal cystic parathyroid adenoma in pregnancy localised with [¹⁸F]fluorocholine PET/CT highlights the diagnostic challenges of primary hyperparathyroidism in pregnancy and supports carefully justified, dose-optimised functional imaging when conventional modalities are inconclusive and surgical decision-making depends on accurate localisation.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13310863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer metastasis to the colon mimicking primary colorectal carcinoma.","authors":"Qingkui Liu, Jianheng Gao, Hongxing Yang, Xiaoshan Chen, Yaqi He","doi":"10.1186/s41824-026-00306-7","DOIUrl":"10.1186/s41824-026-00306-7","url":null,"abstract":"<p><p>Breast cancer metastasis to the colon is rare, occurring in less than 1% of patients with metastatic breast cancer. Invasive lobular carcinoma (ILC) exhibits a distinct tropism for the gastrointestinal tract and adnexa, often presenting with atypical imaging features that mimic primary tumors. We report a case of a 58-year-old woman with a history of right breast ILC who presented with incidental pelvic masses on ultrasound five years after mastectomy. 2-[¹⁸F]FDG PET/CT revealed multifocal hypermetabolic lesions in the transverse colon wall and bilateral adnexa. CT enterography and colonoscopy confirmed a stenotic colonic lesion with smooth mucosa. Postoperative pathology following right hemicolectomy, hysterectomy, and bilateral salpingo-oophorectomy confirmed metastatic breast carcinoma involving the right colon and bilateral adnexa. This case highlights the critical role of PET/CT in detecting occult gastrointestinal metastases in patients with ILC and underscores the importance of considering metastatic disease in the differential diagnosis of colonic lesions in this population.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13269616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.","authors":"Helena F Bruzzi, Gabriela C K Lopes, Hannah B V Bekierman, Sergio Altino de Almeida, José Alexandre Pedrosa, Camila Mosci, Haonne S Abboud, Christiane Magalhães, Isabella Palazzio, Laura Fernandes, Vinicius Freire da Silva, Juliana Tarouquella da Silva Andrade, Daniel Herchenhorn","doi":"10.1186/s41824-026-00305-8","DOIUrl":"10.1186/s41824-026-00305-8","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the approval of 177Lu-PSMA-617 as standard treatment for patients with mCRPC, at least 50% of patients do not respond to the therapy, especially those with visceral disease. This study analyzes real-world outcomes of 177Lu-PSMA-I&T used in heavily pretreated patients in Brazil.</p><p><strong>Methods: </strong>Retrospective analysis of patients with mCRPC previously treated with at least one androgen receptor pathway inhibitor (ARPI) who underwent 177Lu-PSMA-I&T between 2020 and 2025 in two large oncology centers. Our primary endpoint was prostate-specific antigen (PSA) response rate of 50% or more (PSA50). Secondary endpoints included overall survival (OS) and time to next sequential therapies (TNST). Statistical analyses were performed in JAMOVI and RStudio.</p><p><strong>Results: </strong>Forty-three patients were included, with median age 74 years and median baseline PSA 41 ng/mL. Prior to 177Lu-PSMA-I&T, 86% received more than one ARPI line and 23.3% underwent more than one taxane-based chemotherapy. Visceral disease was present in 41.9%. The overall PSA50 response for all patients was 44.2% and for patients with visceral disease was 33.3%. Median OS was 13.9 months [95% confidence interval (CI) 10.9-19.2] and 12-month survival was 55.5% [95% CI 42.1%-73.3%]. Out of the 24 patients who received subsequent therapies, median TNST was 2.9 months [95% CI 1.6-5.4].</p><p><strong>Conclusions: </strong>Our results showed that 177Lu-PSMA-I&T achieved a PSA response comparable to those treated with 177Lu-PSMA-617 in randomized trials, despite our heavily treated patients' characteristics. A significant number of patients had visceral disease with expected lower PSA response, highlighting the need for more active combinations in this subgroup.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13246990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-FAPI PET/CT safely detects multifocal endometriosis: a case report.","authors":"Ghasemali Divband, Arezoo Milani, Masoume Chehrara, Hossein Sharifi, Leila Hassanzadeh","doi":"10.1186/s41824-026-00288-6","DOIUrl":"10.1186/s41824-026-00288-6","url":null,"abstract":"<p><strong>Purpose: </strong>Endometriosis can be tough to diagnose accurately, especially when standard imaging misses hidden lesions. We explored whether ⁶⁸Ga-FAPI-46 PET/CT, a new molecular imaging technique, could spot multifocal endometriosis that conventional methods overlook.</p><p><strong>Methods: </strong>A 28-year-old woman with severe menstrual pain underwent transvaginal ultrasound (TVS), pelvic MRI, and ⁶⁸Ga-FAPI-46 PET/CT. The PET/CT scan was performed 60 minutes after injecting 3 mCi (111 MBq) of ⁶⁸Ga-FAPI-46, targeting fibroblast activation protein (FAP) in fibrotic tissue. We used Monte Carlo simulations (GATE v9.0) to estimate radiation doses to organs, ensuring safety.</p><p><strong>Results: </strong>TVS and MRI detected a right ovarian endometrioma, but ⁶⁸Ga-FAPI-46 PET/CT went further, confirming this lesion (SUVmax 9.5) and revealing two additional nodules in the left adnexa (SUVmax 9.6) that MRI missed. Surgical pathology confirmed multifocal endometriosis. Dosimetry showed a low ovarian radiation dose (0.73 × 10^{- 2} Gy/GBq), proving the procedure's safety for young women.</p><p><strong>Conclusion: </strong>⁶⁸Ga-FAPI-46 PET/CT is a safe and powerful tool for uncovering hidden endometriotic lesions, potentially guiding better surgical planning. While promising, larger studies are needed to confirm its role in routine practice.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life experience in the treatment of gallbladder carcinoma by transarterial radioembolization: a multicenter retrospective study.","authors":"Thomas Dertnig, Roman Kloeckner, Lukas Mueller, Timo Alexander Auer, Arthur J A T Braat, Malte Maria Sieren, Ulf Neumann, Stefan Kasper, Leonie S Jochheim, Benedikt M Schaarschmidt","doi":"10.1186/s41824-026-00304-9","DOIUrl":"10.1186/s41824-026-00304-9","url":null,"abstract":"<p><p>PURPOSE: Patients with liver metastases from gallbladder carcinoma have limited treatment options. This retrospective multicenter study evaluated overall survival, tumor control and safety after transarterial radioembolization in this rare patient group. MATERIALS AND METHODS: Patients with histologically confirmed gallbladder carcinoma and liver-dominant metastatic disease treated with yttrium-90 or holmium-166 radioembolization at five tertiary centres were retrospectively identified. Baseline clinical and imaging data, details of the radioembolization procedure and follow-up imaging were collected. Tumor response was assessed locally using RECIST 1.1. Overall survival was analysed descriptively using Kaplan–Meier curves. RESULTS: Sixteen patients (9 women, mean age 65.7 ± 5.5 years) were included; 93.8% had received prior systemic chemotherapy and 75.0% had extrahepatic metastases. At approximately 3 months, hepatic disease control was achieved in 81.8% (9/11) of patients with available imaging, whereas global disease control was 36.4% (4/11). Median overall survival was 7.1 months (95% confidence interval 1.7–12.3). The median time to hepatic progression was 115 days and the median time to global progression was 112 days. Procedure-related complications were limited to one coil dislocation, one contrast reaction and one liver abscess. CONCLUSION: Radioembolization was feasible and well tolerated in patients with liver-dominant metastases from gallbladder carcinoma and provided intrahepatic disease control in a heavily pretreated population. Given the small sample size, these exploratory findings require confirmation in prospective studies. </p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148019912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and prognostic value of ^99mTc-pyrophosphate SPECT/CT in patients with transthyretin amyloid cardiomyopathy.","authors":"Hidenobu Hashimoto, Rine Nakanishi, Shunsuke Kiuchi, Sunao Mizumura, Yukiko Hashimoto, Takanori Ikeda","doi":"10.1186/s41824-026-00301-y","DOIUrl":"10.1186/s41824-026-00301-y","url":null,"abstract":"<p><p>BACKGROUND: This study evaluated the diagnostic and prognostic values of Technetium- 99m pyrophosphate (99mTc-PYP) scintigraphy using single-photon emission computed tomography/ computed tomography (SPECT/CT) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). METHODS: Among 206 consecutive patients with suspected cardiac amyloidosis who underwent 99mTc-PYP scintigraphy using SPECT/CT and had no evidence of monoclonal protein, 20 patients were diagnosed with ATTR-CM based on SPECT/CT interpretation, whereas183 had no diagnostic findings on SPECT/CT interpretation. We calculated 99mTc-PYP activity in the volume of interest (VOI) for the myocardium and upper aorta for the blood pool as a reference. The heart-to-blood ratio (HBR) was calculated by dividing the mean activity in the VOI of the myocardium by that in the VOI of the upper aorta. Receiver-operating-characteristic (ROC) analysis was used to assess the diagnostic value of the Perugini grade, HBR, and heart-to-contralateral ratio (H/CL). A multivariate Cox model was used to assess whether the parameters, including HBR, were associated with all-cause mortality, cardiac death, and hospitalization for heart failure. RESULTS: By ROC analysis, HBR had the most diagnostic value (HBR area under the curve [AUC]: 0.997, 95% confidence interval [CI] 0.990–1.000 vs. H/CL AUC: 0.9617, 95% CI 0.942–0.981 vs. Perugini grade AUC: 0.918, 95% CI 0.891–0.945). During a mean follow-up period of 531 days, 38 major adverse cardiac events occurred. Multivariable Cox models showed that HBR was the most significant prognostic factor (hazard ratio 2.715, 95% CI 1.185–6.221, p = 0.018). CONCLUSIONS: This study demonstrated that HBR calculated by 99mTc-PYP scintigraphy using SPECT/CT could have potential diagnostic and prognostic value in patients with ATTR-CM. </p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13176378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combating radiophobia: a top priority for the further development of nuclear medicine.","authors":"Panagiotis Georgoulias, George Angelidis, Emmanouil Panagiotidis, Varvara Valotassiou, Ioannis Tsougos","doi":"10.1186/s41824-026-00298-4","DOIUrl":"10.1186/s41824-026-00298-4","url":null,"abstract":"","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3D-ring CZT gamma cameras in theranostics: is it a revolution?","authors":"Hiba Noamen, Yann Cras, Camilo Garcia, Song Hong, Andrei Iagaru, Désirée Deandreis","doi":"10.1186/s41824-026-00300-z","DOIUrl":"10.1186/s41824-026-00300-z","url":null,"abstract":"","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13161408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}